



BELEAVE PROVIDES BUSINESS UPDATE

September 26th, 2016, Toronto, ON – Beleave Inc. (“Beleave” or the “Company”) (CSE: “BE”) is pleased to announce that it has received notification from Health Canada that, upon the Company's confirmation that the Company's proposed site and storage security measures are in place, functional and comply with the requirements of the *Access to Cannabis for Medical Purposes Regulations* (the “ACMPR”) and the Security Directive, Health Canada will prepare to request a pre-licensing inspection of the Company's proposed site. The issuance of a license under the ACMPR is in part dependent upon the completion of a satisfactory pre-licensing inspection by Health Canada of the Company's proposed site.

About Beleave

Beleave Inc. is a biotech company committed to becoming a licensed producer under the ACMPR. Beleave's wholly owned subsidiary First Access Medical Inc. (“FAM”) has applied for a licence to cultivate and sell medical marijuana pursuant to the *Marihuana for Medical Purposes Regulations*, now the ACMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process. Beleave's purpose built facility is located near Hamilton, Ontario. Beleave is traded on the CSE under the symbol BE, with 21,518,355 Common Shares outstanding (33,784,690 on a fully diluted basis).

Forward-Looking Statements

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the ACMPR licensing process, meeting the requirements of the ACMPR, and the start of production. No assurances are given as to the anticipated timing of delivering the confirmations to Health Canada described in this press release nor the anticipated timing of any pre-licensing inspection. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



CONTACT INFORMATION

Beleave Inc.

www.beleave.com

Sebastian de Kloet

+1-905-979-5173

Sebastian@beleave.com